The price of research-grade PT-141 (Bremelanotide) is primarily determined by sequence purity, synthesis scale, and rigorous analytical verification standards. High-purity lyophilized PT-141 verified by RP-HPLC and mass spectrometry reflects the true cost of domestic solid-phase peptide synthesis, endotoxin clearance, and lot-specific third-party testing required for reproducible preclinical research.
The price of research-grade PT-141 (Bremelanotide) is primarily determined by sequence purity, synthesis scale, and rigorous analytical verification standards. High-purity lyophilized PT-141 verified by RP-HPLC and mass spectrometry reflects the true cost of domestic solid-phase peptide synthesis, endotoxin clearance, and lot-specific third-party testing required for reproducible preclinical research.
When evaluating the market price for PT-141 (Bremelanotide acetate), principal investigators and laboratory managers must look beyond unit cost to assess analytical value. Research-grade peptide pricing reflects a combination of manufacturing methods, purity thresholds, quality assurance testing, and domestic supply chain logistics. In the synthesis of cyclic heptapeptides like PT-141, achieving structural fidelity requires complex cyclization steps that significantly impact yield and production expense compared to simple linear peptides.
Discrepancies in PT-141 peptide price across different vendors usually correspond to the depth of quality control executed per batch. Low-cost reagents often bypass necessary purification cycles or rely on unverified overseas toll manufacturers. In contrast, premium reference materials undergo rigorous purification processes to remove truncated sequences, residual reagents, and heavy metal catalysts. Purchasing verified PT-141 10mg ensures that experimental protocols are supported by authentic chemical identity and consistent per-vial mass, minimizing batch-to-batch variability in preclinical trials.
PT-141, structurally designated as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH). Functioning primarily as a non-selective melanocortin agonist, PT-141 exhibits high binding affinity for the melanocortin-3 receptor (MC3R) and melanocortin-4 receptor (MC4R) within the central nervous system. Unlike peripheral vasoactive agents, PT-141 exerts its physiological influence by activating central neuro-signaling cascades.
Preclinical literature indicates that PT-141 bypasses the vascular nitric oxide pathway entirely, acting instead upon hypothalamic nuclei—specifically the paraventricular nucleus (PVN) and medial preoptic area (mPOA). In animal models, activation of central MC4R pathways by PT-141 triggers downstream dopaminergic pathways involved in behavioral appetitive responses and sexual-health signaling circuits. Understanding these precise receptor interactions is critical for researchers designing assays around neuroendocrine signaling, autonomic responses, and central melanocortin receptor function.
The primary cost driver in producing high-grade PT-141 is the efficiency of solid-phase peptide synthesis (SPPS). The synthesis of PT-141 requires step-wise coupling of protected amino acids onto a solid resin support, followed by a critical side-chain-to-side-chain lactam cyclization between the Asp-3 and Lys-8 residues. Cyclization steps inherently possess lower kinetic yields than standard amide bond formations, requiring specialized coupling reagents and extended reaction times.
Following cleavage from the resin matrix, raw crude PT-141 contains various deletion sequences and incomplete cyclization byproducts. Purification via preparative reverse-phase high-performance liquid chromatography (RP-HPLC) is required to isolate the target cyclic peptide. Each additional HPLC purification pass improves product purity toward the baseline >99% standard, but reduces net mass yield. Consequently, the final PT-141 peptide price directly correlates with the degree of purification work required to reach research-grade standards.
To ensure experimental integrity, laboratory reagents must be accompanied by comprehensive documentation. Reliable pricing reflects the integration of multi-tier analytical testing performed by independent, accredited testing facilities. Every lot of research peptides provided by PX1 Research undergoes rigorous verification, ensuring that published specifications match exact vial contents.
Analytical validation for PT-141 includes two core techniques: RP-HPLC to establish purity percentages by measuring UV absorbance relative to impurities, and electrospray ionization mass spectrometry (ESI-MS) to confirm exact molecular weight and structural identity. Furthermore, because bacterial contamination can alter cellular assays and induce non-specific inflammatory responses in animal models, high-grade reagents undergo chromogenic LAL assays to verify strict endotoxin limits (<0.01 EU/mg). These quality control measures account for a meaningful portion of the overall production cost, distinguishing research-grade material from unverified compounds.
Researchers evaluating melanocortin receptor agonists often compare PT-141 with structural ancestors and related analogs within the class. While sharing basic binding profiles, distinct chemical modifications alter their functional selectivity, metabolic half-life, and laboratory cost metrics.
A common comparison involves Melanotan II, from which PT-141 was originally derived as a active metabolite (Bremelanotide). Melanotan II exhibits potent MC1R affinity alongside MC3R/MC4R agonism, driving significant melanogenesis in preclinical models. PT-141 features a modified C-terminal structure that reduces MC1R-mediated pigmentation signaling while retaining potent central MC4R activation. When evaluating melanocortin receptor pathways, researchers selecting between PT-141, Melanotan II, and endogenous alpha-MSH analogs must weigh target receptor selectivity against synthesis complexity and per-milligram pricing structures.
In vitro assays utilizing recombinant human melanocortin receptors demonstrate that PT-141 acts as a full agonist at MC3R and MC4R, with Ki values in the low nanomolar range. In these assays, binding of PT-141 stimulates intracellular cyclic adenosine monophosphate (cAMP) accumulation, confirming active signal transduction through G-protein coupled receptor (GPCR) cascades.
In vivo rodent models have established that central administration (icv) or systemic injection of PT-141 increases c-Fos expression within the medial preoptic area and other limbic structures. These preclinical findings suggest that PT-141 modulates central neurotransmission—specifically augmenting mesolimbic dopamine release—independent of peripheral vascular tone. These experimental models provide foundational data for investigating neuroendocrine control of complex appetitive and autonomic behaviors.
Proper handling and storage are vital to protect lyophilized PT-141 from hydrolytic degradation and peptide aggregation, maintaining the functional value of your laboratory investment. PT-141 is supplied as a lyophilized (freeze-dried) cake or powder under vacuum or inert gas flushing to maximize shelf stability.
For reconstitution in experimental protocols, standard laboratory practice involves adding sterile bacteriostatic water or sterile 0.9% sodium chloride solution. Gentle swirling should be used to dissolve the peptide cake; vigorous agitation or vortexing should be avoided as shear forces can disrupt peptide secondary structures. Once reconstituted, stock solutions should be aliquoted into single-use polypropylene vials to prevent repeated freeze-thaw cycles and stored at -20°C or -80°C for long-term stability. Lyophilized vials should be kept desiccated at -20°C prior to initial reconstitution.
Evaluating a supplier's manufacturing standard is essential when comparing PT-141 peptide prices. Cheap imported compounds often carry hidden costs, such as batch inconsistency, improper counter-ion content, missing trifluoroacetic acid (TFA) clearance, or unannounced heavy metal content. These unverified variables jeopardize research reproducibility and ruin experimental datasets.
PX1 Research maintains strict operational standards to protect laboratory outcomes. All compounds are manufactured in cGMP-compliant US facilities and verified through an ISO 17025 accredited laboratory. Every single lot is backed by a publicly accessible Certificate of Analysis (COA) detailing RP-HPLC purity charts, mass spectral analysis, and endotoxin quantification. Orders ship same-day from distribution centers in California and Arizona, guaranteeing rapid turnaround and cold-chain protection during transit.
For academic institutions, biotechnology organizations, and high-throughput screening labs, managing reagent expenses requires strategic procurement. Purchasing research compounds in unit quantities can increase overall project budgets due to cumulative packaging, handling, and analytical overhead costs.
Establishing a institutional or wholesale account allows research facilities to access volume-tiered pricing structures without sacrificing quality control. High-volume orders benefit from centralized lot reservation, ensuring that multi-phase longitudinal studies utilize identical peptide batches with identical TFA salt content and purity profiles. Reviewing comprehensive technical literature in our research library further assists laboratory managers in matching peptide specifications directly to study requirements.
What determines the price of PT-141 peptide for research?
PT-141 pricing depends on sequence purity levels (e.g., >99%), synthesis scale, solid-phase cyclization yields, trifluoroacetic acid (TFA) removal, and the depth of third-party analytical testing, including RP-HPLC, mass spectrometry, and endotoxin assays.
Is PT-141 supplied as a lyophilized powder or liquid?
Research-grade PT-141 is supplied as a lyophilized (freeze-dried) powder in sealed glass vials. Lyophilization ensures maximum chemical stability during storage and transport prior to laboratory reconstitution.
What is the primary target receptor profile for PT-141?
In preclinical literature, PT-141 acts as a synthetic non-selective melanocortin receptor agonist, exhibiting high binding affinity for MC3R and MC4R within the central nervous system.
Why is third-party COA validation critical when evaluating PT-141 suppliers?
A lot-specific Certificate of Analysis (COA) from an independent ISO 17025 accredited lab confirms peptide purity, structural mass, and endotoxin limits, ensuring that experimental results are not compromised by impurities or improper concentration.
How should PT-141 be stored to maintain long-term stability?
Lyophilized PT-141 should be stored desiccated at -20°C or -80°C. Following reconstitution with sterile bacteriostatic water, stock solutions should be aliquoted and stored frozen to avoid degradation from repeat freeze-thaw cycles.
How does PT-141 differ structurally from Melanotan II?
PT-141 (Bremelanotide) is a active cyclic metabolite of Melanotan II featuring a modified C-terminus. This structural change reduces MC1R affinity (pigmentation pathways) while retaining potent central MC3R/MC4R activation.
What liquid medium is recommended for reconstituting PT-141 for laboratory use?
Reconstitution is typically performed using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile isotonic saline, depending on the requirements of the specific in vitro or in vivo experimental protocol.
Does PX1 Research provide endotoxin testing for PT-141?
Yes. All PX1 Research peptide lots undergo chromogenic LAL testing to verify endotoxin levels meet strict standards (<0.01 EU/mg) for cellular and animal research models.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.